Bashir Ayat, Joseph Nejo, Hammond John S, White Steve, Abu-El-Haija Maisam, Drewes Asbjørn Mohr, Shaw James A M, Pandanaboyana Sanjay
Department of Hepatobiliary Surgery, Freeman Hospital, Newcastle upon Tyne, United Kingdom.
Department of Pediatrics, University of Cincinnati, Division of Gastroenterology, Hepatology and Nutrition, Cincinnati Children's Hospital Medical Center, Cincinnati, OH.
Pancreas. 2025 Mar 1;54(3):e268-e277. doi: 10.1097/MPA.0000000000002424. Epub 2024 Nov 29.
This scoping review aims to provide evidence synthesis of continuous glucose monitoring (CGM) and insulin pump use after undergone total pancreatectomy (TP) with or without islet autotransplantation (TPIAT).
The review was conducted adhering to PRISMA-ScR (Preferred Reporting Items for Systematic reviews and Meta-Analyses extension for Scoping Reviews) checklist.
Fifteen studies including 147 patients (adult n = 71/pediatric n = 76) reported on CGM use post-TP (n = 42) and TPIAT (n = 105). Four were randomized controlled trials and 10 observational studies. Six studies evaluated CGM use in the perioperative and 6 in the immediate postoperative period (n = 8) with variable follow-up (14 hours to 20 months). CGM was used as a stand-alone device (8 studies), which allowed assessment of glycemic variability (n=5) and detection of hypoglycemia (n = 1), resulting in lower glucose levels (n = 1). Six studies evaluated insulin pump with CGM with reduction in postoperative mean glucose (n = 4) and hypoglycemic episodes (n = 2). No patient-reported outcome measures (PROMs) or quality of life (QoL) measures were reported.
CGM can be used following TP for glucose monitoring and/or linked with insulin pump device in the perioperative period with improved glycemic control. However, the data are limited by short follow-up and lack of PROMs and QoL measures.
本范围综述旨在综合分析全胰切除术(TP)伴或不伴胰岛自体移植(TPIAT)后持续葡萄糖监测(CGM)和胰岛素泵使用的证据。
本综述遵循PRISMA-ScR(系统评价和Meta分析扩展的范围综述首选报告项目)清单进行。
15项研究纳入了147例患者(成人71例/儿童76例),报告了TP后(42例)和TPIAT后(105例)CGM的使用情况。其中4项为随机对照试验,10项为观察性研究。6项研究评估了围手术期CGM的使用,6项研究评估了术后即刻(8例)CGM的使用,随访时间不一(14小时至20个月)。CGM作为独立设备使用(8项研究),可评估血糖变异性(5项研究)和检测低血糖(1项研究),并降低血糖水平(1项研究)。6项研究评估了胰岛素泵联合CGM的使用,结果显示术后平均血糖降低(4项研究),低血糖发作减少(2项研究)。未报告患者报告结局指标(PROMs)或生活质量(QoL)指标。
TP术后可使用CGM进行血糖监测和/或在围手术期与胰岛素泵设备联用,以改善血糖控制。然而,数据受随访时间短以及缺乏PROMs和QoL指标的限制。